Extended Data Fig. 3: Reduced suppressive function, reactive oxygen species (ROS) production, and cell growth in Rel^−/− MDSCs.

a,b, Representative flow cytometry plots from the MDSC-T cell suppression assay for Fig. 2a (a) and Fig. 2b (b). c, Growth of bone marrow-derived MDSCs from WT (n = 4 mice/group) and Rel^−/− (n = 9 mice/group) mice. (*, P = 0.03299). d, ROS production by bone marrow-derived MDSCs from WT and Rel^−/− mice (n = 6 mice/group; ***, P < 0.0001). e, Percentages of CD11b⁺Ly6G⁺ and CD11b⁺Ly6C⁺ cells in bone marrow-derived MDSCs from WT and Rel^−/− mice. Data representative of three independent experiments. f, Tumor growth in WT mice injected s.c. with B16F10 tumor cells plus Rel^−/− MDSCs infected with control (n = 5 mice) or Rel-expressing retroviruses (n = 6 mice) (**, P = 0.0041). g, Percentages of CD44^high cells in intratumor CD8⁺ cells of WT mice treated as in panel f. (n = 4 mice/group; *, P = 0.0187). h, The degree of suppression, at the indicated Effector:T cell ratio, of CD8⁺ T cell proliferation by bone marrow-derived MDSCs and BMDMs from naïve mice (n = 3 mice/group). The concentrations of anti-CD3 and anti-CD28 used (125 ng/mL each) were half of those in Fig. 2b (***, P < 0.0001). i, Representative flow cytometry plots for the MDSC-T cell suppression assay for Panel h. Statistical significance was determined by two-tailed unpaired t-test (c-e, g), two-tailed Mann-Whitney U-test (f), or two-way ANOVA with Tukey post-hoc test (h). Data are presented as means ± s.e.m. (c,d,f,h).

Source data